Nanomedicine

2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

Continue Reading...

2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers

The physical mode of action of NBTXR3 may represent a breakthrough approach for the local treatment of liver cancers, as it does not engage liver and renal functions, i.e. nanoparticles are not metabolized and not excreted by kidney. A phase I/II trial has been implemented for the treatment of hepatocellular carcinoma and liver metastasis. […]

Continue Reading...

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

Continue Reading...

2018 – AACR – Activation of the cGAS-STING pathway by NBTXR3

Recent studies reported that radiotherapy could activate the cGAS-STING pathway, which plays a fundamental role in the immune response to cytoplasmic DNA, by activation of the transcriptional factor IRF3, leading to expression of interferon-beta. Moreover, cGAS-STING activation appears to be an important component for tumor resident Antigen-Presenting Cells activation, a crucial step for induction of CD8+ T cell response against tumor derived antigens. […]

Continue Reading...

2017 – Abstract – THNO – NBTXR3 in combination with IMRT in patients with locally advanced HNSCC

At the 2017 THNO in Nice, France, prof. C. Le Tourneau presented preliminary results of NBTXR3 in patients suffering from HNSCC. The treatment was associated with a positive safety profile, and preliminary effiacy evaluation, the local Complete Response rate is 83 % (dose level15% and 22%), with a duration of response of 22 months. […]

Continue Reading...

2017 – Abstract – CTOS – NBTXR3 induces antitumoral immune response in human STS

The enclosed abstract was presented at the “2017 Connective Tissue Oncology Society Annual Meeting (CTOS), Maui, Hawaii”. The abstract “NBTXR3 Treatment Induces Antitumoral Immune Response in Human Soft Tissue Sarcoma” describes how NBTXR3 activated by RT triggers an enhanced adaptive immune response and contributes to transform “cold” tumor into “hot” tumor.

Continue Reading...

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer